Amgen yesterday reported that its profit has risen to 40% compared to Q1 of current fiscal year and the reason being massive restructuring in the organization which even lead to layoff of its employees. Amgen has already positioned itself in top 3 contenders in cancer therapy with its massive pipeline of different types of MAbs (Monoclonal antibodies) and today in Wall Street the news was that GSK is collaborating with Amgen in marketing Denosumab in Europe which is for Postmenopausal Osteoporosis, Amgen is going to receive around $120 Million from this deal. On the other hand this deal will strengthen GSK positions in global cancer therapy segment as its competitor Pfizer is rapidly expanding its portfolio in caner therapy segment.
Wednesday, July 29, 2009
Amgen .................
Amgen yesterday reported that its profit has risen to 40% compared to Q1 of current fiscal year and the reason being massive restructuring in the organization which even lead to layoff of its employees. Amgen has already positioned itself in top 3 contenders in cancer therapy with its massive pipeline of different types of MAbs (Monoclonal antibodies) and today in Wall Street the news was that GSK is collaborating with Amgen in marketing Denosumab in Europe which is for Postmenopausal Osteoporosis, Amgen is going to receive around $120 Million from this deal. On the other hand this deal will strengthen GSK positions in global cancer therapy segment as its competitor Pfizer is rapidly expanding its portfolio in caner therapy segment.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment